The FDA on August 11, 2023, approved the fixed dose combination of AKEEGA® with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated Castration-Resistant Prostate Cancer (mCRPC), as determined by an FDA-approved test. AKEEGA® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
